Skip to main content

divarasib

Generic: Divarasib

divarasib: 7 clinical trials tracked.

divarasib evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about divarasib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence6 indications · 3 study sponsors
Clinical Trials (7)

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT06793215·Phase 3·ENTA
Recruiting

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizedopen600 targetStarted 2025-10Completion 2030-1050 sites · Argentina, Australia, Belgium, Brazil…Hoffmann-La Roche

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082·Phase 1·ENTA
Recruiting

Primary endpoint: Percentage of Participants with Adverse Events (AEs)

InterventionalRandomizedopen320 targetStarted 2023-06Completion 2032-0150 sites · Argentina, Australia, Belgium, Brazil…Hoffmann-La Roche

An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study

NCT05862285·Phase 3·ENTA
Recruiting

Primary endpoint: Number of Participants With Continued Access to Roche IMP(s)-Based Therapy and/or Comparator Agent(s)

Interventionalopen100 targetStarted 2023-06Completion 2033-0350 sites · Belgium, Canada, China, Costa Rica…Hoffmann-La Roche

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

NCT04929223·Phase 1·IGMS
Recruiting

Primary endpoint: Objective Response Rate

InterventionalRandomizedopen542 targetStarted 2021-10Completion 2030-0850 sites · Australia, Canada, Denmark, Germany…Hoffmann-La Roche

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

NCT04589845·Phase 2·ENTA
Recruiting

Primary endpoint: All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

Interventionalopen920 targetStarted 2021-01Completion 2032-0950 sites · United StatesHoffmann-La Roche

NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer

NCT04302025·Phase 2·MRUS
Recruiting

Primary endpoint: Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)

Interventionalopen99 targetStarted 2020-11Completion 2030-0538 sites · United StatesGenentech, Inc.

A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

NCT04449874·Phase 1·ENTA
Active, not recruiting

Primary endpoint: Percentage of Participants With Adverse Events (AEs)

Interventionalopen498 targetStarted 2020-07Completion 2027-1250 sites · Australia, Belgium, Brazil, Canada…Genentech, Inc.